Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDXS Stock Forecast 2026-2027
$2.60
Current Price
$236.33M
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CDXS Price Targets
+323.1%
To High Target of $11.00
+169.2%
To Median Target of $7.00
-23.1%
To Low Target of $2.00
CDXS Price Momentum
+5.3%
1 Week Change
+5.3%
1 Month Change
-10.7%
1 Year Change
+59.5%
Year-to-Date Change
-32.8%
From 52W High of $3.87
+170.8%
From 52W Low of $0.96
📊 TOP ANALYST CALLS
Did CDXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Codexis is one of their latest high-conviction picks.
Latest CDXS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CDXS has a bullish consensus with a median price target of $7.00 (ranging from $2.00 to $11.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $2.60, the median forecast implies a 169.2% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 323.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDXS Analyst Ratings
5
Buy
2
Hold
0
Sell
CDXS Price Target Range
Low
$2.00
Average
$7.00
High
$11.00
Current: $2.60
Latest CDXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 22, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $11.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $11.00 |
| Nov 4, 2024 | Benchmark | Hold | Reiterates | $N/A | |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 29, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 19, 2024 | Benchmark | Hold | Downgrade | $N/A | |
| Aug 9, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 30, 2024 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| May 3, 2024 | Benchmark | Buy | Reiterates | $N/A | |
| Feb 29, 2024 | Benchmark | Buy | Upgrade | $N/A | |
| Nov 7, 2023 | Benchmark | Hold | Downgrade | $N/A | |
| Nov 6, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Sep 1, 2023 | Benchmark | Buy | Reiterates | $N/A | |
| Aug 14, 2023 | Stifel | Buy | Maintains | $N/A | |
| Jul 21, 2023 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| May 9, 2023 | Benchmark | Buy | Maintains | $N/A | |
| May 9, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Apr 17, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 27, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 19, 2023 | Piper Sandler | Overweight | Maintains | $N/A |
Codexis Inc. (CDXS) Competitors
The following stocks are similar to Codexis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Codexis Inc. (CDXS) Financial Data
Codexis Inc. has a market capitalization of $236.33M with a P/E ratio of -5.0x. The company generates $78.09M in trailing twelve-month revenue with a -41.0% profit margin.
Revenue growth is +102.1% quarter-over-quarter, while maintaining an operating margin of -52.7% and return on equity of -68.9%.
Valuation Metrics
Market Cap
$236.33M
Enterprise Value
$232.28M
P/E Ratio
-5.0x
PEG Ratio
0.1x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+102.1%
Gross Margin
+86.5%
Operating Margin
-52.7%
Net Margin
-41.0%
EPS Growth
+102.1%
Financial Health
Cash/Price Ratio
+27.6%
Current Ratio
5.4x
Debt/Equity
168.6x
ROE
-68.9%
ROA
-12.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Codexis Inc. (CDXS) Business Model
About Codexis Inc.
What They Do
Develops sustainable enzymatic solutions for therapeutics.
Business Model
The company generates revenue through its two segments: Performance Enzymes and Novel Biotherapeutics. Performance Enzymes commercializes enzyme products for the pharmaceuticals market, including innovative applications for RNAi therapeutics manufacturing. Novel Biotherapeutics focuses on discovering and enhancing biotherapeutic drug candidates, while also providing enzymes for precision diagnostics and supporting small molecule manufacturing.
Additional Information
Founded in 2002 and based in Redwood City, California, Codexis Inc. utilizes its proprietary CodeEvolver technology to design superior enzymes, reducing waste and improving efficiency. The company's offerings cater to partners in therapeutics development globally, including significant markets in the United States, Europe, and Asia.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
146
CEO
Dr. Alison Moore Ph.D.
Country
United States
IPO Year
2010
Website
www.codexis.comCodexis Inc. (CDXS) Latest News & Analysis
Latest News
Quick Summary
Codexis, Inc. (CDXS) held its Q1 2026 earnings call, discussing financial performance and corporate developments. Further details on revenue and forecasts were provided.
Why It Matters
Codexis, Inc.'s Q1 2026 earnings call reveals financial performance and strategic direction, impacting stock valuation and investor sentiment regarding growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Codexis Reports First Quarter 2026 Financial Results
2 months ago
Quick Summary
Codexis, Inc. reported Q1 revenue of $15.2 million and reiterated its full-year financial guidance. The company will present new data on its ECO Synthesis platform at the upcoming TIDES USA meeting.
Why It Matters
Codexis' strong quarterly revenue and reaffirmed full-year guidance signal stability and growth potential, while upcoming presentations may highlight innovations that attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Codexis (CDXS) reported a quarterly loss of $0.10 per share, beating the Zacks Consensus Estimate of $0.11 and improving from a loss of $0.25 per share a year earlier.
Why It Matters
Codexis' smaller quarterly loss than expected indicates improving financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Codexis, Inc. (CDXS) will present new data on its ECO Synthesis® Manufacturing Platform and regulatory updates at TIDES USA, May 11–14 in Boston.
Why It Matters
Codexis's presentation on its ECO Synthesis® platform and regulatory updates could signal advancements in production efficiency, impacting future revenue and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Codexis (CDXS) is expected to report earnings that may exceed forecasts due to favorable conditions. Investors should prepare for the upcoming earnings report.
Why It Matters
Codexis (CDXS) may exceed earnings expectations, indicating strong performance that could boost stock prices and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Codexis, Inc. reported FY25 revenue of $70.4M, up 19%, aided by a $37.8M deal with Merck. Gross margin rose to 64%, with reduced net loss and SG&A expenses, enhancing financial sustainability.
Why It Matters
Codexis's strong revenue growth and strategic partnerships enhance its market position, while improved margins and reduced losses signal financial health, making it an attractive prospect for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CDXS Stock
What is Codexis Inc.'s (CDXS) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Codexis Inc. (CDXS) has a median price target of $7.00. The highest price target is $11.00 and the lowest is $2.00.
Is CDXS stock a good investment in 2027?
According to current analyst ratings, CDXS has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDXS stock?
Wall Street analysts predict CDXS stock could reach $7.00 in the next 12 months. This represents a 169.2% increase from the current price of $2.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Codexis Inc.'s business model?
The company generates revenue through its two segments: Performance Enzymes and Novel Biotherapeutics. Performance Enzymes commercializes enzyme products for the pharmaceuticals market, including innovative applications for RNAi therapeutics manufacturing. Novel Biotherapeutics focuses on discovering and enhancing biotherapeutic drug candidates, while also providing enzymes for precision diagnostics and supporting small molecule manufacturing.
What is the highest forecasted price for CDXS Codexis Inc.?
The highest price target for CDXS is $11.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 323.1% increase from the current price of $2.60.
What is the lowest forecasted price for CDXS Codexis Inc.?
The lowest price target for CDXS is $2.00 from at , which represents a -23.1% decrease from the current price of $2.60.
What is the overall CDXS consensus from analysts for Codexis Inc.?
The overall analyst consensus for CDXS is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CDXS stock price projections?
Stock price projections, including those for Codexis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 5:06 PM UTC